论文部分内容阅读
作者采用双盲、随机方法对比了静滴伊洛前列素(Iloprost)与口服心痛定治疗系统性硬化患者伴发雷诺氏现象的疗效。 23例系统性硬化伴雷诺氏现象患者,随机12例接受静滴Iloprost,开始为每分钟0.5ng/kg,继之每15分钟增加每分钟0.5ng/kg,直至最大剂量为每分钟2.0ng/kg,用药3天。第8周重复用药1次。11例口服心痛定,开始为每天30mg,4周后加到每天60mg。用药12周。研究结果表明,两种药物均能显著减少雷诺氏现象发作的次数,时间以及严重程度。16周后,Iloprost组手指病变的数量自3.5减到0.6,心痛定组自4.3减到1.4。Ilopr-
The authors compared the efficacy of intravenous Iloprost with oral xintongding in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis by a double-blind, randomized approach. Twenty-three patients with systemic sclerosis and Raynaud’s syndrome randomized 12 patients to receive Iloprost, starting at 0.5 ng / kg per minute, followed by 0.5 ng / kg every 15 minutes until a maximum dose of 2.0 ng / kg, medication for 3 days. Week 8 repeated medication 1 time. 11 cases of oral heartache given, starting 30mg daily, 4 weeks after the addition of 60mg daily. Medication for 12 weeks. The results show that both drugs can significantly reduce the number of Raynaud’s attacks, the time and severity. After 16 weeks, the number of finger lesions in the Iloprost group decreased from 3.5 to 0.6, and the nifedipine group decreased from 4.3 to 1.4. Ilopr-